Rhodes Jason P has filed 89 Form 4 transactions, all in a single company, Dyne Therapeutics (DYN), and every one of them is an open-market sale. The total value of those sales is $129,095,797.43. There are no purchases, no option exercises, and no grants in the record. The pattern is one-directional: Rhodes has sold DYN stock repeatedly and in large blocks, with no corresponding accumulation.
The most recent cluster of sales, 25 in total, spans June 25 through August 14, 2026. The August 14 trades are the largest, with three sales worth $8,061,625, $11,959,425, and $33,991,850, respectively. That single day accounts for roughly $54 million of the total. The August 13 filings add another $11.2 million across three trades. Earlier in the period, the selling was steadier but smaller: seven trades on July 7 ranged from $118,050 to $2,881,861.43, and the June sales, spread across four days, came to roughly $11 million in aggregate.
The dollar values are not trivial, and the frequency is high. Rhodes sold on at least nine separate trading days in under two months. The absence of any buy-side activity, combined with the concentration in one ticker, makes the bias unambiguous. The filings do not indicate whether the shares were held directly or through entities, and the Form 4 codes show no conversions or tax-related withholdings in this window. The record is simply a series of open-market sales, and the recent direction is firmly toward liquidation.
AI-assisted summary